Healthcare

US-based oncology research technology provider Flatiron Health became the latest of GV’s life sciences-focused exits, after a $1.9bn acquisition by pharmaceutical firm Roche.

Pharmaceutical firm Roche agreed to acquire cancer research technology provider Flatiron Health, paying $1.9bn for the remainder of the company’s shares, giving GV, the corporate venturing unit of internet conglomerate Alphabet, its fifth latest life sciences exit since November. At the time of the acquisition, Roche already owned a…Read More.

Ping An Ventures, the corporate venturing unit of China-based insurance group Ping An, is currently seeking to raise $1.3bn in capital for two healthcare-oriented funds. Both funds will invest at growth…

Pharmaceutical company Sanofi is to exit cancer treatment developer Impact Biomedicines, which was acquired by fellow pharmaceutical firm Celgene for $1.1bn up. The transaction is comprised of Celgene…